Enhancing metastatic pMMR colorectal cancer treatments

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses standard treatment approaches based on RAF/BRAF mutations, for patients that have metastatic proficient mismatch repair (pMMR) colorectal cancer. Strategies to improve current treatments include selecting patients eligible for anti-EGFR monoclonal antibodies and integrating immune checkpoint inhibitors in future treatments. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.